Strongbridge Biopharma (SBBP) Upgraded to Buy by BidaskClub

BidaskClub upgraded shares of Strongbridge Biopharma (NASDAQ:SBBP) from a hold rating to a buy rating in a research note released on Wednesday.

Several other equities research analysts have also recently commented on SBBP. Zacks Investment Research cut shares of Strongbridge Biopharma from a hold rating to a sell rating in a research report on Thursday, September 28th. ValuEngine cut shares of Strongbridge Biopharma from a hold rating to a sell rating in a research report on Monday, October 2nd. HC Wainwright reiterated a buy rating and set a $18.00 price target on shares of Strongbridge Biopharma in a research report on Wednesday, November 15th. Finally, Cantor Fitzgerald started coverage on shares of Strongbridge Biopharma in a research report on Tuesday, December 5th. They set a buy rating and a $14.00 price target for the company. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and five have given a buy rating to the stock. The stock currently has a consensus rating of Buy and an average price target of $12.25.

Shares of Strongbridge Biopharma (NASDAQ SBBP) opened at $6.75 on Wednesday. Strongbridge Biopharma has a 1 year low of $2.00 and a 1 year high of $8.85. The company has a debt-to-equity ratio of -1.89, a quick ratio of 4.61 and a current ratio of 4.70. The company has a market cap of $268.73 and a P/E ratio of -2.00.

A number of hedge funds and other institutional investors have recently modified their holdings of SBBP. Caxton Corp boosted its holdings in shares of Strongbridge Biopharma by 2.2% in the third quarter. Caxton Corp now owns 5,514,994 shares of the biotechnology company’s stock valued at $38,053,000 after buying an additional 120,000 shares during the period. Lyon Street Capital LLC bought a new position in shares of Strongbridge Biopharma in the third quarter valued at about $2,862,000. Northern Trust Corp bought a new position in shares of Strongbridge Biopharma in the second quarter valued at about $1,462,000. Nexthera Capital LP bought a new position in shares of Strongbridge Biopharma in the second quarter valued at about $477,000. Finally, Vanguard Group Inc. bought a new position in shares of Strongbridge Biopharma in the second quarter valued at about $474,000. Hedge funds and other institutional investors own 57.53% of the company’s stock.

WARNING: “Strongbridge Biopharma (SBBP) Upgraded to Buy by BidaskClub” was originally published by Community Financial News and is the sole property of of Community Financial News. If you are reading this report on another publication, it was copied illegally and republished in violation of United States and international trademark and copyright laws. The legal version of this report can be viewed at https://www.com-unik.info/2017/12/28/strongbridge-biopharma-sbbp-upgraded-to-buy-by-bidaskclub.html.

Strongbridge Biopharma Company Profile

Strongbridge Biopharma plc is a global commercial-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies for a range of diseases. The Company’s commercial product, KEVEYIS (dichlorphenamide), is indicated for the treatment of hyperkalemic, hypokalemic and related variants of primary periodic paralysis.

Receive News & Ratings for Strongbridge Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Strongbridge Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit